<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909935</url>
  </required_header>
  <id_info>
    <org_study_id>09-02-0067</org_study_id>
    <nct_id>NCT00909935</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of Dexmedetomidine in Children</brief_title>
  <official_title>The Pharmacokinetics of Dexmedetomidine in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to identify the plasma concentrations which are required to achieve&#xD;
      adequate sedation, using a Ramsay Sedation Scale. As an alpha 2 agonist, dexmedetomidine can&#xD;
      elicit hemodynamic changes, fluctuations in blood pressure and heart rate. This study will&#xD;
      attempt to determine whether these changes can be predicted by plasma concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine, an alpha2 agonist is currently the standard of care for sedation for&#xD;
      diagnostic (MRI, CT and Nuclear Medicine) radiological studies at Boston Children's Hospital.&#xD;
      Although it is FDA approved for sedation, its pharmacokinetics in children has not been&#xD;
      carefully studied with prospective studies. The plasma concentration of dexmedetomidine&#xD;
      necessary to achieve and maintain adequate sedation for motionless conditions for a MRI study&#xD;
      has not been determined which is the purpose of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to enroll enough patients&#xD;
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of dexmedetomidine in pediatric patients</measure>
    <time_frame>2012-2015</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>MRI Sedation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.</description>
    <other_name>Precedex</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children requiring sedation for MRI scanning&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 3 - 11.9 years&#xD;
&#xD;
               -  2 age groups: 3.0 - 5.9 years, 6.0 - 11.9 years&#xD;
&#xD;
          -  Patients will be equally distributed within each age group&#xD;
&#xD;
          -  Meets criteria to receive dexmedetomidine sedation for MRI:&#xD;
&#xD;
               -  Active, uncontrolled gastroesophageal reflux - an aspiration risk&#xD;
&#xD;
               -  Active, uncontrolled vomiting - an aspiration risk&#xD;
&#xD;
               -  Current (or within past 3 months) history of apnea requiring an apnea monitor&#xD;
&#xD;
               -  Active, current respiratory issues that are different from the baseline status&#xD;
                  (pneumonia,exacerbation of asthma, bronchiolitis, respiratory syncytial virus)&#xD;
&#xD;
               -  Unstable cardiac status (life threatening arrhythmias, abnormal cardiac&#xD;
                  anatomy,significant cardiac dysfunction)&#xD;
&#xD;
               -  Craniofacial anomaly, which could make it difficult to effectively establish a&#xD;
                  mask airway for positive pressure ventilation if needed&#xD;
&#xD;
               -  Current use of digoxin&#xD;
&#xD;
               -  Moya Moya Disease&#xD;
&#xD;
               -  New-onset stroke&#xD;
&#xD;
               -  Provide written consent to take part in the research study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Do not meet established sedation criteria&#xD;
&#xD;
          -  History of allergy, intolerance, or reaction to dexmedetomidine or hypersensitivity&#xD;
&#xD;
          -  Previous diagnosis of hepatic insufficiency/failure or a serum glutamate pyruvate&#xD;
             transaminase level &gt; 2 times the normal limit determined by Children's Hospital Boston&#xD;
             (TCH)&#xD;
&#xD;
          -  Current diagnosis of renal insufficiency/failure or a current serum creatinine level &gt;&#xD;
             1.5 times the normal limit determined by TCH&#xD;
&#xD;
          -  Have received digoxin in the past (no time limit)&#xD;
&#xD;
          -  Received phenobarbital, clonidine or valproic acid within 30 days&#xD;
&#xD;
          -  Current, repaired or risk of Moya-Moya disease&#xD;
&#xD;
          -  Recent stroke (cerebrovascular accident) within past 6 months&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Concomitant use of beta antagonist, or calcium channel blocker&#xD;
&#xD;
          -  Participated in a clinical investigation within the past three months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keira P. Mason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Keira Mason</investigator_full_name>
    <investigator_title>Senior Associate in Perioperative Anesthesia</investigator_title>
  </responsible_party>
  <keyword>To determine pharmacokinetics of dexmedetomidine in children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

